Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig ...Middle East

NANJING, China, Sept. 12, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in a Phase 1b/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB...

Hence then, the article about indication expansion accelerates first patient dosed in melanoma phase 1b ii trial of opamtistomig was published today ( Friday 12/09/2025 - 07:37 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Indication Expansion Accelerates: First Patient Dosed in Melanoma Phase 1b/II Trial of Opamtistomig )

Also on site :

• Taylor Frankie Paul Shares Vacation Pics of Kids Amid Custody Drama
• Caesars Just Launched a $200-Per-Night All-Inclusive Deal on the Strip—And It Includes Celebrity Chef Dining
• Iran executes two convicted members of banned opposition group